SCHEMBL16559554

SCHEMBL16559554

CC[C@H](OCc1ccccc1)C(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
KMT2A Q03164 4/20 0.45
SLC1A3 P43003 2/20 0.45
SLC1A2 P43004 2/20 0.45
SLC1A1 P43005 2/20 0.45
MEN1 O00255 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
PSMB5 P28074 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 1/20 0.44
LTA4H P09960 1/20 0.44
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16672540 1.00 ALDH1A1 (0.49) ALDH1A1KMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL16672561 0.88 ALDH1A1 (0.55) ALDH1A1KMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL9902801 0.87 L3MBTL1 (0.51) ALDH1A1KMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL28851016 0.87 PSMB5 (0.54) ALDH1A1KMT2AMEN1CYP2C9CYP2C19
SCHEMBL28851015 0.87 PSMB5 (0.54) ALDH1A1KMT2AMEN1CYP2C9CYP2C19
SCHEMBL7900470 0.87 ALDH1A1 (0.49) ALDH1A1KMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL15528161 0.84 SLC1A3 (0.53) ALDH1A1KMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL2384187 0.84 SLC1A3 (0.53) ALDH1A1KMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL1273202 0.84 SLC1A3 (0.53) ALDH1A1KMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL16672702 0.84 LMNA (0.47) ALDH1A1KMT2ASLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346820-B2 HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands PURDUE RESEARCH FOUNDATION (US) 2016-05-24 US disclosed
US-20150072958-A1 HIV-1 PROTEASE INHIBITORS HAVING GEM-DI-FLUORO BICYCLIC P2-LIGANDS PURDUE RESEARCH FOUNDATION 2015-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150072958-A1 HIV-1 PROTEASE INHIBITORS HAVING GEM-DI-FLUORO BICYCLIC P2-LIGANDS PREP, DPEP1, BACE1 ALDH1A1 1487/4885KMT2A 2083/4885SLC1A3 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.